Search Results - "Brody, Jonathan Robert"

Validation of the PDACai signature in predicting relative benefit from frontline FOLFIRINOX (FFX) and gemcitabine/nab-paclitaxel (GA) for patients (pts) with metastatic pancreatic cancer (mPDAC) by Pishvaian, Michael J., Blais, Edik Matthew, Thach, Dzung, Brody, Jonathan Robert, Matrisian, Lynn McCormick, Halverson, David Charles, DeArbeloa, Patricia, Rocha, Flavio G, Hendifar, Andrew Eugene, Petricoin, Emanuel

“…4149 Background: Nearly 50% of pts with mPDAC never receive a 2nd line of therapy for metastatic disease following frontline FFX or GA. Genomic alterations in…”
Get full text

Association of pancreatic adenocarcinoma location (head/body/tail) with DDR mutation status and response to platinum-based therapy by Micaily, Ida, Blais, Edik Matthew, Cohen, Steven J, Cannaday, Shawnna, Krampitz, Geoffrey, Wadlow, Raymond Couric, Shroff, Rachna T., McRee, Autumn Jackson, Chuy, Jennifer W., Zheng, Lei, Hendifar, Andrew Eugene, Matrisian, Lynn McCormick, Gregory, Gary Lee, Thach, Dzung, Brody, Jonathan Robert, Petricoin, Emanuel, Pishvaian, Michael J., Lavu, Harish, Yeo, Charles, Basu Mallick, Atrayee

“…Abstract only 612 Background: Pancreatic adenocarcinoma is an aggressive disease with poor clinical prognosis that can originate from either the head (H) or…”
Get full text

NeoOPTIMIZE: An open-label, phase II trial and biomarker discovery platform to assess the efficacy of adaptive switching of modified FOLFIRINOX (mFFX) or gemcitabine/nab-paclitaxel (GA) as a neoadjuvant strategy for patients with resectable/borderline resectable and locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC) by Lopez, Charles D., Kardosh, Adel, Chen, Emerson Yu-sheng, Mayo, Skye C., Eil, Robert, Worth, Patrick Joseph, Gilbert, Erin W., Rocha, Flavio G., Nabavizadeh, Nima, Grossberg, Aaron, Guimaraes, Alexander, Foster, Bryan, Brinkerhoff, Brian, Goodyear, Shaun, Taber, Erin, Keith, Dove, Brody, Jonathan Robert, Mills, Gordon B., Sears, Rosalie, Sheppard, Brett C.

“…Abstract only TPS630 Background: Neoadjuvant chemotherapy (NAC) and/or chemo-RT may confer benefit to patients with localized PDAC, by better tolerability,…”
Get full text

Comprehensive analysis of KRAS variants in patients (pts) with pancreatic cancer (PDAC): Clinical/molecular correlations and real-world outcomes across standard therapies by Hendifar, Andrew Eugene, Blais, Edik Matthew, Ng, Camille, Thach, Dzung, Gong, Jun, Sohal, Davendra, Chung, Vincent, Sahai, Vaibhav, Fountzilas, Christos, Mikhail, Sameh, Gregory, Gary, Brody, Jonathan Robert, Lyons, Emily, DeArbeloa, Patricia, Matrisian, Lynn McCormick, Petricoin, Emanuel, Pishvaian, Michael J.

“…Abstract only 4641 Background: Approximately 90% of PDAC tumors are driven by activating KRAS mutations. The biological and clinical impact of common KRAS…”
Get full text

Real-world outcomes in pancreatic adenocarcinoma (PDAC) and persona types with implications for standard of care (SOC) therapy (Tx) by Petricoin, Emanuel, Pishvaian, Michael J., DeArbeloa, Patricia, Barg, Daniel, Thach, Dzung, Brody, Jonathan Robert, Matrisian, Lynn McCormick, Chung, Vincent, Hendifar, Andrew Eugene, Mikhail, Sameh, Sohal, Davendra, Blais, Edik Matthew

“…Abstract only 735 Background: Molecular profiling (MP) for PDAC has gained increased acceptance and we previously demonstrated that targeting actionable…”
Get full text

Final report of a phase I/II study of veliparib (Vel) in combination with 5-FU and oxaliplatin (FOLFOX) in patients (pts) with metastatic pancreatic cancer (mPDAC) by Pishvaian, Michael J., Wang, Hongkun, Parenti, Sarah, He, Aiwu Ruth, Hwang, Jimmy J., Ley, Lisa, Difebo, Holly, Smaglo, Brandon George, Kim, Sunnie S., Weinberg, Benjamin Adam, Weiner, Louis M., Marshall, John, Brody, Jonathan Robert

“…Abstract only 4015 Background: 17 – 25% of mPDACs harbor DNA damage response (DDR) mutations, the presence of which can be predictive of a response to platinum…”
Get full text

Improved overall survival (OS) for advanced pancreatic cancer (PDAC) patients (pts) enrolled in the Know Your Tumor (KYT) program whose tumors harbored highly actionable molecular alterations and who received molecularly-matched therapies (tx) by Pishvaian, Michael J., Blais, Edik Matthew, DeArbeloa, Patricia, Brody, Jonathan Robert, Rahib, Lola, Hendifar, Andrew Eugene, Mikhail, Sameh, Chung, Vincent, Sohal, Davendra, Picozzi, Vincent J., Mason, Kimberly, Tibbetts, Lisa, Lyons, Emily, Matrisian, Lynn McCormick, Madhavan, Subha, Petricoin, Emanuel

“…Abstract only 4138 Background: Initial results from the KYT program demonstrated that 27% of PDACs harbor highly actionable molecular alterations (herein…”
Get full text

Outcomes in pancreatic adenocarcinoma (PDA) patients (pts) with genetic alterations in DNA damage repair (DDR) pathways: Results from the Know Your Tumor (KYT) program by Pishvaian, Michael J., Blais, Edik Matthew, Brody, Jonathan Robert, Sohal, Davendra, Hendifar, Andrew Eugene, Chung, Vincent, Mikhail, Sameh, Rahib, Lola, Lyons, Emily, Tibbetts, Lisa, Madhavan, Subha, Matrisian, Lynn McCormick, Petricoin, Emanuel

“…Abstract only 191 Background: Up to 17% of PDAs harbor mutations in the DDR pathway. However, the purely prognostic relevance of these mutations is unclear…”
Get full text

Precision medicine for pancreatic cancer patients:preliminary results from the know your tumor program by Petricoin, Emanuel, Bender, R Joseph, Halverson, David Charles, Rahib, Lola, Hendifar, Andrew Eugene, Mikhail, Sameh, Chung, Vincent M., Picozzi, Vincent J., Sohal, Davendra, Matrisian, Lynn McCormick, Brody, Jonathan Robert, Madhavan, Subha, Pishvaian, Michael J.

“…Abstract only…”
Get full text

Multi-Omic profiling (MoP) for patients (pts) with pancreatic cancer (PDA): Initial results of the Know Your Tumor (KYT) initiative by Pishvaian, Michael J., Brody, Jonathan Robert, Matrisian, Lynn, Hendifar, Andrew Eugene, Engebretson, Anitra, Hoos, William Arthur, Mikhail, Sameh, Chung, Vincent M., Picozzi, Vincent J., Ramos, Corinne, Heartwell, Craig, Mason, Kimberly, Varieur, Katelyn, Rahib, Lola, Petricoin, Emanuel, Madhavan, Subha

“…Abstract only 282 Background: Emerging insights into the molecular biology of tumors and recent developments in MoP have led to the identification of targets…”
Get full text

Preliminary observations of blood-based (BB) molecular testing in a subset of patients with pancreatic cancer (PDA) participating in the Know Your Tumor (KYT) initiative by Pishvaian, Michael J., Matrisian, Lynn, Hendifar, Andrew Eugene, Engebretson, Anitra, Rahib, Lola, Hoos, William Arthur, Mikhail, Sameh, Chung, Vincent M., Picozzi, Vincent J., Heartwell, Craig, Mason, Kimberly, Varieur, Katelyn, Madhavan, Subha, Petricoin, Emanuel, Brody, Jonathan Robert

“…Abstract only 268 Background: Obtaining an adequate tissue sample for molecular profiling to guide therapy selection for patients with advanced cancers can be…”
Get full text

The Know Your Tumor (KYT) initiative: A national program of multi-omic molecular profiling (MoP) for patients (Pts) with pancreatic cancer (PDA) by Engebretson, Anitra, Brody, Jonathan Robert, Rahib, Lola, Matrisian, Lynn, Hendifar, Andrew Eugene, Hoos, William Arthur, Mikhail, Sameh, Chung, Vincent M., Picozzi, Vincent J., Heartwell, Craig, Mason, Kimberly, Varieur, Katelyn, Madhavan, Subha, Petricoin, Emanuel, Pishvaian, Michael J.

“…Abstract only 279 Background: There has been a significant increase in the utilization of MoP to facilitate the selection of therapies for pts with advanced…”
Get full text

Molecular biomarkers as predictors of patient survival in pancreatic adenocarcinoma (PDA): An analysis of the Know Your Tumor initiative (KYT) by Bender, R Joseph, Halverson, David, Mason, Kimberly, Luo, Linlin, Brody, Jonathan Robert, Rahib, Lola, Matrisian, Lynn McCormick, Hendifar, Andrew Eugene, Hoos, William Arthur, Mikhail, Sameh, Chung, Vincent M., Picozzi, Vincent J., Ramos, Corinne, Heartwell, Craig, Varieur, Katelyn, Aberra, Metasebia, Petricoin, Emanuel, Madhavan, Subha, Pishvaian, Michael J.

“…Abstract only 278 Background: Recent studies have expanded our knowledge of the genomic landscape of PDA. While critical and in some cases, potentially…”
Get full text

A pilot study of molecularly tailored therapy for patients with metastatic pancreatic cancer (MPC) by Pishvaian, Michael J., Wang, Hongkun, He, Aiwu Ruth, Ley, Lisa, Dorsch-Vogel, Karen, Hartley, Marion L., Carney, Erin, Weiner, Louis M., Smaglo, Brandon George, Brody, Jonathan Robert, Marshall, John

“…Abstract only 329 Background: We have entered an era where multiple chemotherapeutic (chemo) agents can be utilized in the treatment (Tx) of patients (pts)…”
Get full text

A comparison of the WHO 2004 and 2010 classification systems in pancreatic neuroendocrine tumors (PNET) by Sama, Ashwin Reddy, Asija, Aakanksha, Casey, James, Andrel-Sendecki, Jocelyn, Lewis, Nancy, Lavu, Harish, Winter, Jordan Michael, Brody, Jonathan Robert, Mitchell, Edith P., Yeo, Charles, Prestipino, Anthony, Pillai, Madhavan V.

“…Abstract only 267 Background: PNETs are rare tumors with multiple classification systems. We compared the WHO 2004 and 2010 classification systems for…”
Get full text

A comparison of the WHO 2004 and 2010 classification systems in pancreatic neuroendocrine tumors (PNET) by Asija, Aakanksha, Sama, Ashwin Reddy, Casey, James, Andrel Sendecki, Jocelyn, Lewis, Nancy, Lavu, Harish, Winter, Jordan Michael, Brody, Jonathan Robert, Mitchell, Edith P., Yeo, Charles, Prestipino, Anthony, Pillai, Madhavan V.

“…Abstract only…”
Get full text

Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma? by Valsecchi, Matias Emanuel, Littman, Susan Joy, Holdbrook, Thomas, Leiby, Benjamin, Mitchell, Edith P., Yeo, Charles, Brody, Jonathan Robert, Witkiewicz, Agnieszka

“…Abstract only 246 Background: RRM1 and ERCC1 overexpression has been extensively investigated as potential predictive markers of tumor sensitivity to…”
Get full text

Leveraging the DNA damage and transcriptional-regulatory roles of PARP-1 as a means to improve prostate cancer therapy by Schiewer, Matthew Joseph, Steffen, Jamin, Tholey, Renee, Brody, Jonathan Robert, Pascal, John, Lin, Jianqing, Den, Robert, Feng, Felix Yi-Chung, Gomella, Leonard G., Dicker, Adam, Kelly, William Kevin, Knudsen, Karen E.

“…Abstract only 179 Background: The first described roles for PARP-1 were in the repair of DNA damage and genomic maintenance, however, recent studies have…”
Get full text

A phase I/II study of ABT-888 in combination with 5-fluorouracil (5-FU) and oxaliplatin (Ox) in patients with metastatic pancreatic cancer (MPC) by Pishvaian, Michael J., Wang, Hongkun, Zhuang, Tingting, He, Aiwu Ruth, Hwang, Jimmy J., Hankin, Amy, Ley, Lisa, White, Keisha, Littman, Susan Joy, Weiner, Louis M., Marshall, John, Brody, Jonathan Robert

“…Abstract only 147 Background: The PARP inhibitor, ABT-888 is a potent sensitizing agent for, and has been safely combined with DNA-damaging chemotherapies. The…”
Get full text

pp32 (ANP32A) in differentiation and cancer by Brody, Jonathan Robert

“…The pp32 (ANP32) gene family contains at least 4 closely related members-pp32, pp32r1, pp32r2, and April. Although the transcripts and proteins encoded by the…”
Get full text